Poststroke Depression: A Learning Opportunity

Abstract A significant proportion of stroke survivors experience depression-like symptoms, which are debilitating and disabling for the majority. The numbers show that this figure runs into 30% of subjects. This is not a new phenomenon and is well documented by practitioners and researchers alike since the early days. These conditions are compounded by secondary problems such as sleep disorders, irritability, and the increased risk of relapses surrounding neurovascular accidents. Advancements in brain imaging and radiological investigations have significantly improved the diagnosis and early identification of these conditions. We now know the increased significance of lesion location and laterality in poststroke depression (PSD) patients. This has also allowed us to come up with pharmacological and therapeutic opportunities to treat patients effectively. In this review of literature, we begin by defining. In this review of literature, we begin by defining what PSD is and what are its main features and components. We then move on to the biological basis of PSD as well as poststroke apathy, and then consider all the animal models that have been studied to gain insight into PSD, and the use cases of selective serotonin reuptake inhibitors to facilitate treatment. We also go on to explain how antidepressants work to reverse the changes and the lesions that are associated with PSD. We also define diagnostic features that help us in identifying PSD. We also considered patients with vascular depressions that are divided on the basis of age and other demographics. We also test out the potential methods for determining how brain networks are altered and look at the diagnostic criteria for determining how PSD is seen in most individuals.